TrialJournal of translational medicine2020

ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer.

J A Kyte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.